Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 12Thoracic 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Diarrhea 1Colitis 1Breast Neoplasms 1

Interventions

pembrolizumab 21Cyclophosphamide 18fludarabine 8Radiotherapy 8Radiosurgery 7Nivolumab 7poly ICLC 6fludarabine phosphate 6aldesleukin 6Therapeutics 6Paclitaxel 6Magnetic Resonance Spectroscopy 6durvalumab 5Psychiatric Rehabilitation 5Interleukin-2 5Drug Therapy 5Docetaxel 5Cisplatin 5temsirolimus 4cemiplimab 4Trastuzumab 4Temozolomide 4Sirolimus 4Gemcitabine 4Flow Cytometry 4Filgrastim 4Carboplatin 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Loperamide × Dermatologic × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡